Compounded tirzepatide,
delivered everywhere.

Major US metro areas

Cora Health serves the 20 largest US metropolitan areas with dedicated landing pages covering local healthcare context, state pharmacy regulations, neighborhood-level coverage, and metro-specific FAQs.

• New York City New York →
• Los Angeles California →
• Chicago Illinois →
• Dallas-Fort Worth Texas →
• Houston Texas →
• Washington DC Virginia →
• Philadelphia Pennsylvania →
• Miami Florida →
• Atlanta Georgia →
• Boston Massachusetts →
• San Francisco Bay Area California →
• Phoenix Arizona →
• Inland Empire California →
• Detroit Michigan →
• Seattle Washington →
• Minneapolis-St. Paul Minnesota →
• Tampa Bay Florida →
• San Diego California →
• Denver Colorado →
• Baltimore Maryland →

Find compounded tirzepatide in your state

Each state page includes specific availability information, local pricing, FAQs about telehealth GLP-1 in that state, and details on Cora Health's coverage in your area. Click your state below to view the dedicated landing page.

Northeast

• Connecticut →
• Delaware →
• Maine →
• Maryland →
• Massachusetts →
• New Hampshire →
• New Jersey →
• New York →
• Pennsylvania →
• Rhode Island →
• Vermont →

South

• Alabama →
• Arkansas →
• Florida →
• Georgia →
• Kentucky →
• Louisiana →
• Mississippi →
• North Carolina →
• Oklahoma →
• South Carolina →
• Tennessee →
• Texas →
• Virginia →
• West Virginia →

Midwest

• Illinois →
• Indiana →
• Iowa →
• Kansas →
• Michigan →
• Minnesota →
• Missouri →
• Nebraska →
• North Dakota →
• Ohio →
• South Dakota →
• Wisconsin →

West

• Alaska →
• Arizona →
• California →
• Colorado →
• Hawaii →
• Idaho →
• Montana →
• Nevada →
• New Mexico →
• Oregon →
• Utah →
• Washington →
• Wyoming →

About Cora Health's compounded tirzepatide program

Cora Health connects patients with board-certified providers (Wasef Health, PC) for personalized GLP-1 weight loss treatment. The Premium Plan provides compounded tirzepatide at $135/month on the annual commitment — covering the licensed-provider consultation, the medication, free expedited shipping anywhere in the US, and ongoing provider support. There is no separate membership fee, no per-dose price increase, and no in-person visit required for most patients.

Compounded tirzepatide contains the same molecule (tirzepatide, a dual GLP-1/GIP receptor agonist) as brand-name Mounjaro and Zepbound, but it is prepared by state-licensed compounding pharmacies rather than the original brand manufacturer. Compounded medications are not FDA-approved and have not been independently trialed. Clinical trial data for FDA-approved tirzepatide (such as the 22.5% mean weight loss reported in the SURMOUNT-1 trial) reflects studies of the branded product, not compounded versions. Individual results vary.

For a full breakdown of compounded vs brand-name GLP-1 medications, see our complete comparison guide. To learn more about how tirzepatide works, see the complete guide.